Indian manufacturers can produce 34.8 mn RT-PCR combo kits per month: Govt

Quoting an ICMR survey, Ashwini Choubey said Indian manufacturers can manufacture around 34.8 million RT-PCR test kits per month

medicos, doctors, coronavirus, coronavirus tests, doctors, coronavirus, coronavirus tests, doctors, coronavirus
Medics work on samples collected from media professionals for COVID-19 tests, at a special testing centre set up by the Delhi government, during the nationwide lockdown to curb the spread of coronavirus, at Patel Nagar in New Delhi. Photo: PTI
Press Trust of India New Delhi
2 min read Last Updated : Sep 23 2020 | 8:27 PM IST

Indian manufacturers can produce around 3.48 crore RT-PCR combo kits per month, which gives the country a capacity to conduct around 11.35 lakh RT-PCR COVID-19 tests daily, the government said on Wednesday.

The Central Drugs Standard Control Organisation (CDSCO) has granted manufacturing licenses for RT-PCR kits to 30 companies and import licenses to 119 firms, Minister of State for Health Ashwini Choubey said in a written reply.

Quoting an ICMR survey, he said Indian manufacturers can manufacture around 348.1 lakh RT-PCR test kits per month.

"During March to June 2020, around 60 per cent of RT-PCR kits procured were from foreign manufacturers and the remaining 40 per cent were from Indian manufacturers.

"However, currently, 100 per cent procurement of RT-PCR combo kits is from Indian manufacturers, whereas the COBAS, CBNAAT etc kits are still being imported," he said.

The minister was responding to a question on the percentage of kits that are being manufactured indigenously and imported.

In response to another question, Choubey said the ICMR has informed that based on the current manufacturing capacity of Indian manufacturer, around 11.35 lakh RT-PCR combo tests can be conducted per day.

The 30 companieswhich have been granted manufacturing licenses for COVID-19 RT-PCR kits by the CDSCO include Mylab, Molbio Diag. Pvt Ltd, Kilpest India Ltd, Cosara Diagnostics Pvt. Ltd, Huwel Lifesciences Pvt Ltd, Ubio Biotechnology System Pvt Ltd, Affigenix Biosolutions Pvt Ltd, Biosystems Diag. Pvt Ltd, Tata Medical and Diagnostic Ltd and Athenes Dx Pvt Ltd.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsAshwini ChoubeyICMRHealth Ministry

First Published: Sep 23 2020 | 8:01 PM IST

Next Story